A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Must have received: immunomodulatory drug

Receipt of at least two prior classes of drugs... An immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug.

Must have received: proteasome inhibitor

Receipt of at least two prior classes of drugs... An immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug.

Must have received: anti-CD38 drug

Receipt of at least two prior classes of drugs... An immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug.

Cannot have received: targeted therapy (small molecule)

Targeted therapy with small molecule drug within 2 weeks or 5 half-lives, whichever is longer

Cannot have received: targeted therapy (macromolecular)

Targeted therapy with macromolecular drug or Immunomodulatory agent therapy within 2 weeks

Cannot have received: immunomodulatory drug

Immunomodulatory agent therapy within 2 weeks

Cannot have received: chemotherapy

Chemotherapy within 2 weeks

Cannot have received: investigational drug

Treatment with an investigational drug within 2 weeks or 5 half-lives, whichever is shorter

Cannot have received: radiation therapy

Radical/extensive radiotherapy within 4 weeks, or local palliative radiotherapy within 2 weeks, or acute toxicity induced by previous radiotherapy have not recovered to grade ≤1

Cannot have received: autologous stem cell transplantation

Autologous stem cell transplantation within 12 weeks

Cannot have received: allogeneic stem cell transplantation

Allogeneic stem cell transplantation within 6 months

Cannot have received: organ transplant

History of organ transplant

Cannot have received: BCMA-targeted therapy

Prior treatment with any B cell maturation antigen (BCMA) targeted therapy

Cannot have received: BCMA-targeted CAR-T cell therapy

Prior treatment with any BCMA targeted chimeric antigen receptor modified [CAR]-T cells therapy